• Mashup Score: 3

    Your access to the latest cardiovascular news, science, tools and resources.

    Tweet Tweets with this article
    • #ImageOfTheWeek was submitted by Chathurika Samarakoon Kempitiya, K.A Peiris, W. Abeysenavi, M.B.F. Rahuman and N. Fernando from the National Hospital of Sri Lanka, Colombo. What is the diagnosis? https://t.co/1ikgfBeX7F #cardioed #ESCYoung #cardiology #cardiovascular https://t.co/vZq3rmCziH

  • Mashup Score: 2

    For decades, there has been controversy about whether testosterone therapy has deleterious effects on the risk of major cardiovascular events in older men. As the number of prescriptions for testosterone therapy has escalated, this controversy has heightened.1 Although some epidemiological studies have suggested an association between testosterone therapy and risk of major cardiovascular events, an equal (or greater) number of epidemiological studies have demonstrated no increase or even a decreased risk associated with testosterone therapy.

    Tweet Tweets with this article
    • In the Current Issue: Bradley D Anawalt comments on: The #TRAVERSE trial: #cardiovascular safety of #testosterone therapy for older men https://t.co/Asgu6IGajt #hypogonadism

  • Mashup Score: 3

    The life history theory assumes that all organisms are under selective pressure to harvest external resources and allocate them to maximise fitness: only organisms making the best use of energy obtain the greatest fitness benefits. The trade-off of energy spans four functions: maintenance, growth, reproduction, and defence against pathogens. The innovative antihyperglycaemic agents glucagon-like peptide 1 (GLP-1) receptor agonists and sodium-glucose cotransporter 2 (SGLT2) inhibitors decrease bodyweight and have the potential to counter low-grade inflammation.

    Tweet Tweets with this article
    • Personal View: #Glucose-lowering #drugs with #cardiovascular benefits as modifiers of critical elements of the human life history https://t.co/FdnQia5S6d #diabetes #obesity #SGLT2 inhibitors #GLP-1 receptor agonists

  • Mashup Score: 1

    Objective To evaluate the association between recently raised anticholinergic burden and risk of acute cardiovascular events in older adults. Design Case-case-time-control study (ie, incorporating a case crossover design and a control crossover design consisting of future cases). Setting Taiwan’s National Health Insurance Research Database. Participants 317 446 adults aged ≥65 who were admitted to hospital because of an incident acute cardiovascular event between 2011 and 2018. Acute cardiovascular events included myocardial infarction, strokes, arrhythmias, conduction disorders, and cardiovascular death. Main outcome measures The anticholinergic burden was measured for each participant by adding up the anticholinergic scores for individual drugs using the Anticholinergic Cognitive Burden Scale. Scores were classified into three levels (0 points, 1-2 points, and ≥3 points). For each participant, anticholinergic burden levels during hazard periods (day −1 to −30 before the cardiovascula

    Tweet Tweets with this article
    • Recent raised anticholinergic (medications) burden appears to be associated with increased risk of acute #cardiovascular events: Taiwanese nationwide case-case-time-control study ⁦@bmj_latest⁩ https://t.co/iy9BLIvAf7